|
1
|
Si X, Li P, Zhang Y, Zhang Y, Lv W and Qi
D: Renoprotective effects of olmesartan medoxomil on diabetic
nephropathy in streptozotocin-induced diabetes in rats. Biomed Rep.
2:24–28. 2014.PubMed/NCBI
|
|
2
|
Downs CA and Faulkner MS: Toxic stress,
inflammation and symptomatology of chronic complications in
diabetes. World J Diabetes. 6:554–565. 2015.PubMed/NCBI
|
|
3
|
Barutta F, Bruno G, Grimaldi S and Gruden
G: Inflammation in diabetic nephropathy: Moving toward clinical
biomarkers and targets for treatment. Endocrine. 48:730–742. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
García-García PM, Getino-Melián MA,
Domínguez-Pimentel V and Navarro-González JF: Inflammation in
diabetic kidney disease. World J Diabetes. 5:431–443. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yi B, Hu X, Zhang H, Huang J, Liu J, Hu J,
Li W and Huang L: Nuclear NF-κB p65 in peripheral blood mononuclear
cells correlates with urinary MCP-1, RANTES and the severity of
type 2 diabetic nephropathy. PLoS One. 9:e996332014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ahad A, Ganai AA, Mujeeb M and Siddiqui
WA: Ellagic acid, an NF-κB inhibitor, ameliorates renal function in
experimental diabetic nephropathy. Chem Biol Interact. 219:64–75.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang SM, Ka SM, Wu HL, Yeh YC, Kuo CH, Hua
KF, Shi GY, Hung YJ, Hsiao FC, Yang SS, et al: Thrombomodulin
domain 1 ameliorates diabetic nephropathy in mice via
anti-NF-κB/NLRP3 inflammasome-mediated inflammation, enhancement of
NRF2 antioxidant activity and inhibition of apoptosis.
Diabetologia. 57:424–434. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ahad A, Ahsan H, Mujeeb M and Siddiqui WA:
Gallic acid ameliorates renal functions by inhibiting the
activation of p38 MAPK in experimentally induced type 2 diabetic
rats and cultured rat proximal tubular epithelial cells. Chem Biol
Interact. 240:292–303. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu JS, Shi R, Lu X, Ma YM and Cheng NN:
Combination of active components of Xiexin decoction ameliorates
renal fibrosis through the inhibition of NF-κB and TGF-β1/Smad
pathways in db/db diabetic mice. PLoS One. 10:e01226612015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gui D, Huang J, Guo Y, Chen J, Chen Y,
Xiao W, Liu X and Wang N: Astragaloside IV ameliorates renal injury
in streptozotocin-induced diabetic rats through inhibiting
NF-κB-mediated inflammatory genes expression. Cytokine. 61:970–977.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nishikawa T, Brownlee M and Araki E:
Mitochondrial reactive oxygen species in the pathogenesis of early
diabetic nephropathy. J Diabetes Investig. 6:137–139. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kamiyama M, Urushihara M, Morikawa T,
Konishi Y, Imanishi M, Nishiyama A and Kobori H: Oxidative
stress/angiotensinogen/renin-angiotensin system axis in patients
with diabetic nephropathy. Int J Mol Sci. 14:23045–23062. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu J, Wang C, Liu F, Lu Y and Cheng J:
Metabonomics revealed xanthine oxidase-induced oxidative stress and
inflammation in the pathogenesis of diabetic nephropathy. Anal
Bioanal Chem. 407:2569–2579. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tabur S, Korkmaz H, Eren MA, Oğuz E,
Sabuncu T and Aksoy N: Urotensin-II level and its association with
oxidative stress in early diabetic nephropathy. J Diabetes
Complications. 29:115–119. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mao ZM, Shen SM, Wan YG, Sun W, Chen HL,
Huang MM, Yang JJ, Wu W, Tang HT and Tang RM: Huangkui capsule
attenuates renal fibrosis in diabetic nephropathy rats through
regulating oxidative stress and p38MAPK/Akt pathways, compared to
α-lipoic acid. J Ethnopharmacol. 173:256–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pal PB, Sinha K and Sil PC: Mangiferin
attenuates diabetic nephropathy by inhibiting oxidative stress
mediated signaling cascade, TNFα related and mitochondrial
dependent apoptotic pathways in streptozotocin-induced diabetic
rats. PLoS One. 9:e1072202014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kolati SR, Kasala ER, Bodduluru LN,
Mahareddy JR, Uppulapu SK, Gogoi R, Barua CC and Lahkar M: BAY
11–7082 ameliorates diabetic nephropathy by attenuating
hyperglycemia-mediated oxidative stress and renal inflammation via
NF-κB pathway. Environ Toxicol Pharmacol. 39:690–699. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang B, Li XP, Ni YF, Du HY, Wang R, Li
MJ, Wang WC, Li MM, Wang XH, Li L, et al: Protective effect of
isorhamnetin on lipopolysaccharide-induced acute lung injury in
mice. Inflammation. 39:129–137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen TL, Zhu GL, Wang JA, Zhang GD, Liu
HF, Chen JR, Wang Y and He XL: Protective effects of isorhamnetin
on apoptosis and inflammation in TNF-α-induced HUVECs injury. Int J
Clin Exp Pathol. 8:2311–2320. 2015.PubMed/NCBI
|
|
20
|
Dou W, Zhang J, Li H, Kortagere S, Sun K,
Ding L, Ren G, Wang Z and Mani S: Plant flavonol isorhamnetin
attenuates chemically induced inflammatory bowel disease via a
PXR-dependent pathway. J Nutr Biochem. 25:923–933. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Manu KA, Shanmugam MK, Ramachandran L, Li
F, Siveen KS, Chinnathambi A, Zayed ME, Alharbi SA, Arfuso F, Kumar
AP, et al: Isorhamnetin augments the anti-tumor effect of
capeciatbine through the negative regulation of NF-κB signaling
cascade in gastric cancer. Cancer Lett. 363:28–36. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qian C, Zhu C, Yu W, Jiang X and Zhang F:
High-fat diet/low-dose streptozotocin- induced type 2 diabetes in
rats impacts ostegenesis and Wnt signaling in bone marrow stromal
cells. PLoS One. 10:e01363902015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zimmet P, Alberti KG and Shaw J: Global
and societal implications of the diabetes epidemic. Nature.
414:782–787. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ruggenenti P, Cravedi P and Remuzzi G: The
RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat
Rev Nephrol. 6:319–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brenner BM, Cooper ME, de Zeeuw D, Keane
WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z and
Shahinfar S: RENAAL Study Investigators: Effects of losartan on
renal and cardiovascular outcomes in patients with type 2 diabetes
and nephropathy. N Engl J Med. 345:861–869. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim B, Choi YE and Kim HS: Eruca sativa
and its flavonoid components, quercetin and isorhamnetin, improve
skin barrier function by activation of peroxisome
proliferator-activated receptor (PPAR)-α and suppression of
inflammatory cytokines. Phytother Res. 28:1359–1366. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang JH, Shin BY, Han JY, Kim MG, Wi JE,
Kim YW, Cho IJ, Kim SC, Shin SM and Ki SH: Isorhamnetin protects
against oxidative stress by activating Nrf2 and inducing the
expression of its target genes. Toxicol Appl Pharmacol.
274:293–301. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dong GZ, Lee JH, Ki SH, Yang JH, Cho IJ,
Kang SH, Zhao RJ, Kim SC and Kim YW: AMPK activation by
isorhamnetin protects hepatocytes against oxidative stress and
mitochondrial dysfunction. Eur J Pharmacol. 740:634–640. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Duran-Salgado MB and Rubio-Guerra AF:
Diabetic nephropathy and inflammation. World J Diabetes. 5:393–398.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lazaro I, Oguiza A, Recio C, Mallavia B,
Madrigal-Matute J, Blanco J, Egido J, Martin-Ventura JL and
Gomez-Guerrero C: Targeting HSP90 ameliorates nephropathy and
atherosclerosis through suppression of NF-κB and STAT signaling
pathways in diabetic mice. Diabetes. 64:3600–3613. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sakai N and Wada T: Revisiting
inflammation in diabetic nephropathy: The role of the Nlrp3
inflammasome in glomerular resident cells. Kidney Int. 87:12–14.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jin JY, Choi EY, Park HR, Choi JI, Choi IS
and Kim SJ: Isorhamnetin inhibits Prevotella intermedia
lipopolysaccharide-induced production of interleukin-6 in murine
macrophages via anti-inflammatory heme oxygenase-1 induction and
inhibition of nuclear factor-κB and signal transducer and activator
of transcription 1 activation. J Periodontal Res. 48:687–695.
2013.PubMed/NCBI
|
|
33
|
Muchová J, Országhová Z, Žitnanová I,
Trebatický B, Breza J and Duracková Z: The effect of natural
polyphenols on the oxidative stress markers in patients with
diabetic nephropathy. Free Radic Biol Med. 75(Suppl 1): S422014.
View Article : Google Scholar
|
|
34
|
Verma AK, Chandra S, Singh RG, Singh TB,
Srivastava S and Srivastava R: Serum prolidase activity and
oxidative stress in diabetic nephropathy and end stage renal
disease: a correlative study with glucose and creatinine. Biochem
Res Int. 2014:2914582014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gomes IB, Porto ML, Santos MC, Campagnaro
BP, Pereira TM, Meyrelles SS and Vasquez EC: Renoprotective,
anti-oxidative and anti-apoptotic effects of oral low-dose
quercetin in the C57BL/6J model of diabetic nephropathy. Lipids
Health Dis. 13:1842014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mima A: Inflammation and oxidative stress
in diabetic nephropathy: new insights on its inhibition as new
therapeutic targets. J Diabetes Res. 2013:2485632013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bao M and Lou Y: Isorhamnetin prevent
endothelial cell injuries from oxidized LDL via activation of
p38MAPK. Eur J Pharmacol. 547:22–30. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Han X, Piao MJ, Kim KC, Madduma Hewage SR,
Yoo ES, Koh YS, Kang HK, Shin JH, Park Y, Yoo SJ, et al:
Isorhamnetin Protects Human Keratinocytes against Ultraviolet
B-Induced Cell Damage. Biomol Ther (Seoul). 23:357–366. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ding Y, Yang H, Xiang W, He X, Liao W and
Yi Z: CD200R1 agonist attenuates LPS-induced inflammatory response
in human renal proximal tubular epithelial cells by regulating
TLR4-MyD88-TAK1-mediated NF-κB and MAPK pathway. Biochem Biophys
Res Commun. 460:287–294. 2015. View Article : Google Scholar : PubMed/NCBI
|
